Selective Serotonin Reuptake Inhibitors (SSRIs) antidepressants use in hot flashes in oncology;Place des antidépresseurs sérotoninergiques dans la prise en charge des bouffées de chaleur en cancérologie

Revue de Medecine Interne

Volumn 25, Issue 3, 2004, Pages 217-224

  Elek, T ^a   Reich, M ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Breast cancer; Hot flushes; Prostate cancer; Serotonin; SSRIs antidepressant

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; CLONIDINE; CYPROTERONE ACETATE; FLUOXETINE; MEGESTROL ACETATE; MIRTAZAPINE; NORSET; PAROXETINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; VENLAFAXINE; VERALIPRIDE; ZOLPIDEM; ZOLPIDEM TARTRATE;

ANOREXIA; ANXIETY DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CASTRATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL OBSERVATION; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERABILITY; GALACTORRHEA; GYNECOMASTIA; HOT FLUSH; HUMAN; INSOMNIA; LIVER TOXICITY; MENOPAUSE; NAUSEA AND VOMITING; NERVOUSNESS; ONCOLOGY; PARESTHESIA; PATHOPHYSIOLOGY; PHLEBITIS; PRESCRIPTION; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREATMENT INDICATION; VERTIGO;

EID: 1442351102     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.revmed.2003.11.004     Document Type: Short Survey

References (65)

1. Greendale G.A., Lee N.P., Arriola E.R. The menopause. Lancet. 353:1999;571-580.
2. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 14:1996;1718-1729.
3. Nowak H. Retentissement des traitements du cancer du sein sur la fertilité Espié M., Gorins A. Le sein du normal au pathologique: état de l'art. 2001;Eska, Paris.
4. Carpenter J.S., Andrykowski M.A., Cordova M., Cunningham L., Studts J., McGrath P. Hot flashes in postmenopausal women treated for breast carcinoma. Cancer. 82:1998;1682-1691.
5. Loprinzi C.L., Zahasky K.M., Sloan J.A., Novotny P.J., Quella S.K. Tamoxifen induced hot flashes. Clin Breast Cancer. 1:2000;52-56.
6. Couzi R.J., Helzlsouer K.J., Fetting J.H. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 13:1995;2737-2744.
7. Tellier P., Godeau P. Ménopause et hormonothérapie substitutive. Rev Méd Interne. 21:2000;445-457.
8. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol. 3:2002;303-311.
9. McLeod D.G., Vogelzang N.J. Initial management of metastatic prostate cancer. Androgen blockade: monotherapy and quality of life issues. 2nd ed Vogelzang N.J., Scardino P.T., Shipley W.U., Coffey D.S. Comprehensive textbook of genito-urinary oncology. 2000;Lippincott Williams and Wilkins, Philadelphia.
10. Charig C.R., Rundle J.S. Flushing long-term side effect of orchidectomy in treatment of prostatic carcinoma. Urology. 33:1989;175-178.
11. Spetz A.-C., Hammar M., Lindberg B., Spangberg A., Varenhorst E. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol. 166:2001;517-520.
12. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 52:2002;154-179.
13. Hedlund P.O., Henriksson P. Parenteral estrogens vs total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology. 55:2000;328-333.
14. Karling P., Hammar M., Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 152:1994;1170-1173.
15. Kouriefs C., Georgiou M., Ravi R. Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int. 89:2002;379-383.
16. Garai J. Hepatic dysfonction in development of menopausal hot flushes? Med Hypotheses. 58:(6):2002;535.
17. Spetz A.C., Hammar M., Petterson W., Varenhorst E. Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int. 90:2002;476.
18. Casper R.F., Yen S.S.C. Neuro-endocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol. 22:1985;293-312.
19. Joffe H., Cohen S. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry. 44:1998;798-811.
20. Rubinow D.R., Schmidt P.J., Roca C.A. Estrogen-serotonin interactions: implication for affective regulation. Biol Psychiatry. 44:1998;839-850.
21. Duffy L.S., Greenberg D.B., Younger J., Ferraro M.G. Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics. 40:1999;304-308.
22. Thompson D.S., Spanier C.A., Vogel V.G. The relationship between tamoxifen, estrogen, and depressive symptoms. Breast J. 5:1999;375-382.
23. Ragson N.L., Altshuler L.L., Fairbanks L.A., Dunkin J.J., Davtyan C., Elman S., et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry. 63:(Suppl 7):2002;45-48.
24. Eriksson E., Andersch B., Ho H.P., Landén M., Sundblad C. Diagnosis and treatment of premenstrual dysphoria. J Clin Psychiatry. 63:(Suppl 7):2002;16-23.
25. Limosin F., Ades J. Aspects psychiatriques et psychologiques du syndrome prémenstruel. Encéphale. 27:2001;501-508.
26. Dimmock P.W., Wyatt K.M., Jones P.W., O'Brien S. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 356:2000;1131-1136.
27. Hahn P.M., Wong J., Reid R.L. Menopausal-like hot flashes reported in women of reproductive age. Fertil Steril. 70:1998;913-918.
28. Wisner K.L., Parry B.L., Piontek C.M. Postpartum depression. N Engl J Med. 347:2002;194-199.
29. Ahokas A., Kaukoranta J., Wahlbeck K., Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17-beta-estradiol: a preliminary study. J Clin Psychiatry. 62:2001;332-336.
30. Gregoire A.J.P., Kumar R., Everitt B., Henderson A.F., Studd J.W.W. Transdermal estrogen for treatment of severe postnatal depression. Lancet. 347:1996;930-933.
31. Berendsen H.H. The role of serotonin in hot flushes. Maturitas. 36:2000;155-164.
32. McEwen B.S., Alves S.E. Estrogen actions in the central nervous system. Endocr rev. 20:1999;279-307.
33. Roth A.J., Scher H.I. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psycho-oncology. 7:1998;129-132.
34. Stearns V., Isaacs C., Rowland J., Crawford J., Ellis M.J., Kramer R., et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. Ann Oncol. 11:2000;17-22.
35. Weitzner M.A., Moncello J., Jacobsen P.B., Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage. 23:2002;337-345.
36. Waldinger M.D., Berendsen H.H., Schweitzer D.H. Treatment of hot flushes with mirtazapine: four case reports. Maturitas. 36:2000;165-168.
37. Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 20:2002;1578-1583.
38. Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., LaVasseur B.I., Barton D.L. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 356:2000;2059-2063.
39. Stearns V., Beebe K.L., Iyengar M., Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes a randomised controlled trial. JAMA. 289:2003;2827-2834.
40. Loprinzi C.L., Pisansky T.M., Fonsesca R., Sloan J.A., Zahasky K.M., Quella S.K. Pilot evaluation of venlafaxine Hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 16:1998;2377-2381.
41. Quella S.K., Loprinzi C.L., Sloan J., Novotny P., Perez E.A., Burch P.A. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 162:1999;98-102.
42. Sloan J.A., Loprinzi C.L., Novotny P.J., Barton D.L., Lavaseur B.I., Windschitl H. Methodologic lessons learned from hot Flash studies. J Clin Oncol. 19:2001;4280-4290.
43. Quella S.K., Loprinzi C.L., Sloan J.A., Vaught N.L., DeKrey W.L., Fischer T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 82:1998;1784-1788.
44. Olie J.P., Loo H. Les maladies dépressives. 2003;Flammarion, Paris.
45. Kaplan H.I., Sadock B.J. Médicaments en psychiatrie. 2003;Pradel, Paris.
46. Rose R.C., Lane R.M., Menza M. Effects of SSRI's on sexual function: a critical review. J Clin Psychopharmacol. 19:(1):1999;67-85.
47. Tamam L., Ozpoyraz N. Selective Serotonin Reuptake Inhibitor discontinuation syndrome: a review. Adv Ther. 19:(1):2002;17-26.
48. Loprinzi C.L., Michalak J.C., Quella S.K., O'Fallon J.R., Hatfield A.K., Nelimark R.A., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 331:1994;347-352.
49. Loprinzi C.L., Barton D.L., Rhodes D.D. Management of hot flashes in breast-cancer survivors. Lancet Oncol. 2:2001;199-204.
50. Kouriefs C., Georgiou M., Ravi R. Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int. 89:2002;379-383.
51. Boulot P., Viala J.L. A multicenter comparison of veralipride vs placebo in the vasomotor flushes of menopause. An evaluation of the prolonged effect. Rev Fr Gynecol Obstet. 83:1988;823-827.
52. Dargent D. Efficacité et tolérance clinique et biologique de l'administration à long terme du veralipride. À propos de 74 observations. Rev Fr Gynecol Obstet. 80:(3):1985;171-173.
53. Barton D.L., Loprinzi C.L., Quella S.K., Sloan J.A., Veeder M.H., Egner J.R., et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 16:1998;495-500.
54. Goldberg R.M., Loprinzi C.L., O'Fallon Jr, Veeder M.H., Miser A.W., Mailliard J.A., et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 12:1994;155-158.
55. Coope J., Williams S., Patterson J.S. A study of the effectiveness of propranolol in menopausal hot flushes. Br J Obstet Gynaecol. 85:1978;472-475.
56. Quella S.K., Loprinzi C.L., Barton D.L., Knost J.A., Sloan J.A., LaVasseur B.I., et al. Evaluation of soy phyto-estrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 18:2000;1068-1074.
57. Moyad M.A. Complementary-alternative therapies for reducing hot flashes in prostate cancer patients reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology. 59:(Suppl 4A):2002;20-33.
58. Loprinzi C.L., Barton D.L., Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet Oncol. 2:2001;199-204.
59. Wymenga A.N., Sleijfer D.T. Management of hot flushes in breast cancer patients. Acta Oncol. 41:2002;269-275.
60. Jacobson J.S., Troxel A.B., Evans J., Klaus L., Kinne D., Lo K.M., et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 19:2001;2739-2745.
61. Tice J.A., Ettinger B., Ensrud K., Wallace R., Blackwell T., Cummings S.R. Phyto-estrogen supplements for the treatment of hot flashes: the isoflavone clover extract (ICE) Study. JAMA. 290:2003;207-214.
62. Han K.K., Soares J.M. Jr, Haidar M.A., de Lima G.R., Baracat E.C. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol. 99:2002;389-394.
63. van de Weijer P.H.M., Barentsen R. Isoflavone from red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas. 42:2002;187-193.
64. Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controled trial. JAMA. 288:2002;321-333.
65. Carter G.T., Sullivan M.D. Antidepressants in pain management. Curr Opin Investig Drugs. 3:2002;454-458.